Experimental cocktail aims to silence Life-Threatening food allergies

NCT ID NCT06369467

Ongoing Disease control Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests two drugs together—linvoseltamab and dupilumab—in just 6 adults with severe food allergies. The goal is to see if the combination is safe and can lower IgE antibodies that trigger allergic reactions. Participants must have a history of anaphylaxis to foods like peanuts, milk, or shellfish. The trial focuses on safety and side effects, not yet on curing the allergy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: linvoseltamab and dupilumab
What this could lead to: If it works, this could point toward a way to reduce or eliminate severe allergic reactions to foods like peanuts, milk, and shellfish.
What could go wrong: This is a very early, tiny Phase 1 trial with only 6 people. It is primarily checking safety, not effectiveness. The combination may cause side effects or fail to reduce allergies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

EAST syndrome food allergy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOOD ALLERGY

Contacts and locations

Locations

Emory University - Winship Cancer Institute

Atlanta, Georgia, 30322, United States
Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
The Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104, United States
University of South Florida

Tampa, Florida, 33613, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.